Risk Estimation for Recurrent Clostridium difficile Infection Based on Clinical Factors

被引:70
作者
D'Agostino, Ralph B., Sr. [1 ]
Collins, Sylva H. [2 ]
Pencina, Karol M. [1 ]
Kean, Yin
Gorbach, Sherwood [2 ]
机构
[1] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
[2] Cubist Pharmaceut, Lexington, MA USA
关键词
Clostridium difficile infection; CDI; fidaxomicin; vancomycin; INTEGRATED DISCRIMINATION; NET RECLASSIFICATION; VANCOMYCIN; EPIDEMIOLOGY; FIDAXOMICIN; DIARRHEA; DISEASE; METRONIDAZOLE; MANAGEMENT; CARE;
D O I
10.1093/cid/ciu107
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The incidence of Clostridium difficile infection (CDI) has risen dramatically during the last decade. Although patients respond well to medical therapy such as vancomycin, 20%-30% of patients treated suffer a recurrence of CDI. Methods. We developed a simple/practical scoring rule (logistic regression model) for recurrent CDI using data from 2 large phase 3 clinical trials. Seventy-seven baseline CDI factors were classified: demographics, comorbidity, medications, vital signs, laboratory tests, severity, and symptoms. Predictors with the highest discrimination in each class (using receiver operating characteristics curve) were selected. For the final model, stepwise selection was performed. Discrimination, calibration, and internal validation were used to assess the model. Results. The final model with a simple scoring rule was developed. It includes 4 independent risk factors that are readily available when the patient makes initial contact: age (<75 vs >= 75 years), number of unformed bowel movements during previous 24 hours (<10 vs >= 10), serum creatinine leves (< 1.2 mg/dL vs >= 1.2 mg/dL) and prior episode of CDI (yes vs no). In addition, the model includes choice of treatment (vancomycin or fidaxomicin). Conclusions. The prediction model for recurrence may be useful for treatment decision.
引用
收藏
页码:1386 / 1393
页数:8
相关论文
共 32 条
[1]   Prediction Tools for Unfavourable Outcomes in Clostridium difficile Infection: A Systematic Review [J].
Abou Chakra, Claire Nour ;
Pepin, Jacques ;
Valiquette, Louis .
PLOS ONE, 2012, 7 (01)
[2]  
[Anonymous], 2000, WILEY PS TX, DOI 10.1002/0471722146
[3]  
Barbut F, 2000, J CLIN MICROBIOL, V38, P2386
[4]   The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection [J].
Bartlett, John G. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (10) :1489-1492
[5]   Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial [J].
Cornely, Oliver A. ;
Crook, Derrick W. ;
Esposito, Roberto ;
Poirier, Andre ;
Somero, Michael S. ;
Weiss, Karl ;
Sears, Pamela ;
Gorbach, Sherwood .
LANCET INFECTIOUS DISEASES, 2012, 12 (04) :281-289
[6]   General cardiovascular risk profile for use in primary care - The Framingham Heart Study [J].
D'Agostino, Ralph B. ;
Vasan, Ramachandran S. ;
Pencina, Michael J. ;
Wolf, Philip A. ;
Cobain, Mark ;
Massaro, Joseph M. ;
Kannel, William B. .
CIRCULATION, 2008, 117 (06) :743-753
[7]   Burden of Clostridium difficile on the Healthcare System [J].
Dubberke, Erik R. ;
Olsen, Margaret A. .
CLINICAL INFECTIOUS DISEASES, 2012, 55 :S88-S92
[8]   Effect of vancomycin on intestinal flora of patients who previously received antimicrobial therapy [J].
Edlund, C ;
Barkholt, L ;
OlssonLiljequist, B ;
Nord, CE .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (03) :729-732
[9]  
Fekety R, 1997, AM J GASTROENTEROL, V92, P739
[10]   Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin [J].
Figueroa, Iris ;
Johnson, Stuart ;
Sambol, Susan P. ;
Goldstein, Ellie J. C. ;
Citron, Diane M. ;
Gerding, Dale N. .
CLINICAL INFECTIOUS DISEASES, 2012, 55 :S104-S109